EGCG (Epigallocatechin Gallate)

Plain-language summaryIntrigue 60 / 100

EGCG is the principal catechin polyphenol in green tea. It has been studied extensively for cancer prevention, longevity, and metabolic effects. High-dose isolated EGCG carries some hepatotoxicity risk that whole green tea does not. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundGeneric nutrient

32/100

Mature green tea catechin with broad but promiscuous activity and consistently modest clinical translation

Look, EGCG has been the main character of green tea research for 30-plus years, and that tenure is both its credential and its problem. It’s genuinely the dominant catechin in unfermented tea, accounting for up to 80% of catechin content, and the early cell biology was exciting enough to generate thousands of papers. The NF-kB inhibition story, the reactive oxygen species scavenging, the modulation of cancer signaling pathways – all real. But “broad antioxidant and anti-inflammatory” is exactly the description that serious bench scientists have learned to treat with caution.

The mechanism problem with EGCG is promiscuity. It hits too many targets with not enough specificity to serve as a clean research probe. When a compound inhibits NF-kB, modulates p53, chelates metals, and scavenges radicals simultaneously, attributing any observed effect to a specific mechanism becomes genuinely difficult. This isn’t a knock on the chemistry – it’s a real limitation for investigators trying to isolate a causal story. The newer angle on DYRK1A inhibition, with the Spanish TRISOMY21 trial exploring EGCG in Down syndrome, is probably the most mechanistically focused work in the recent literature, but even there EGCG’s selectivity profile is a liability compared to more specific DYRK1A inhibitors now emerging from academic and biotech groups.

Bioavailability is the other persistent issue. Plasma concentrations after oral dosing are low – the compound undergoes extensive first-pass metabolism, the predominant circulating forms are conjugates, and the gap between what you dose and what reaches target tissue is real and substantial. This explains why the clinical literature is so inconsistent. Preclinical data in rodents looks reasonably interesting. Human data is modest, mixed, and frequently confounded by dose, formulation, and baseline differences across study populations.

We’ve seen enough of the clinical picture now to say: EGCG has real biology, but translation has disappointed relative to preclinical promise. There are positive lipid and body composition signals in meta-analyses, modest cognitive effects in scattered trials, and genuine hepatotoxicity risk at concentrated high-dose formulations that limits what investigators can responsibly test. EFSA flagged this and issued guidance limits for a reason, and that ceiling sits uncomfortably close to where effects start appearing in some studies.

Honestly, if you’re studying NF-kB biology, there are cleaner tools. If you’re studying polyphenol pharmacokinetics, EGCG is a reasonable model compound. If you’re studying DYRK1A, the selective inhibitors coming out of academic programs give you better probe quality. The research value is real but narrow, and the compound sits firmly in the established-not-exciting tier. Dont reach for it first.

Novelty: 22
Mechanism promise: 28
In-category differentiation: 32
Evidence quality: 48
Translational signal: 32
Research bench value: 33

Rationale EGCG’s decades-old literature and promiscuous polyphenol mechanism score it low on novelty and bench probe quality; a large but inconsistent evidence base, hampered by poor bioavailability, keeps translational signal modest despite extensive preclinical coverage.

Tea catechin polyphenol

The principal catechin polyphenol of green tea with broad antioxidant and anti-inflammatory activity.

Abstract

EGCG (epigallocatechin-3-gallate; CAS 989-51-5; molecular formula C22H18O11; molecular weight 458.37) is the principal catechin polyphenol of green tea, accounting for 50 to 80 percent of total catechin content in unfermented tea. The compound has broad pharmacological activity: direct antioxidant, anti-inflammatory through NF-kB inhibition, modulation of multiple cancer-related pathways, and modest cardiovascular and metabolic effects. Bioavailability is poor; plasma EGCG concentrations after oral administration are low. Doses for cognitive and metabolic applications are typically 200 to 800 mg per day. Hepatotoxicity has been reported with concentrated EGCG products at high doses (typically over 800 mg/day on an empty stomach), prompting EFSA dosing limits.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-196Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.